Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
8th grade Avg
|
New words:
aim, antibody, Astra, basic, Camilla, CHMP, chronic, Columbia, congenital, COUNSEL, deficiency, digit, DILUTION, disorder, DISPLAY, Doug, email, error, Factor, fraud, FVII, Green, HISTORY, Iceland, inapplicable, Innate, intensified, Jakob, Januay, knowledge, Langa, left, mail, mealtime, Medicinal, milestone, Norway, open, option, Ozempic, prevalence, programme, realised, Rebinyn, Refixia, respond, retired, SA, SELLING, stake, succeeded, succeeding, Sylvest, TABULAR, upfront, user, VIIa, window, wns, Zeneca
Removed:
antidiabetic, approving, arising, austerity, bearer, Belgium, BLA, Caraco, cardiovascular, challenging, clinically, component, Darou, decline, DEVOTE, DNA, endorsed, erode, exir, exposed, franchise, Germany, grown, Hedjat, Helal, impacting, index, infringing, introduced, Italy, JP, liquid, longer, NOVOb, NovoNorm, OAD, observed, originator, Paddock, Pakhsh, Pharmaplan, potency, Prandin, prefilled, professional, purity, recall, represent, short, Similarly, smaller, SOHA, Spain, steadily, subdivision, submitted, subsequently, Sudan, Sudanese, supporting, Syrian, undergo, Union, varying
Filing tables
Filing exhibits
NVO similar filings
Filing view
External links
Exhibit 15.3
Consent of independent registered public accounting firm
We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (No. 333-82318 and No. 333-83724) of Novo Nordisk A/S of our report dated February 1, 2018 relating to the Consolidated Financial Statements and the effectiveness of internal control over financial reporting, which appears in this Form 20-F.
/s/ PricewaterhouseCoopers
Statsautoriseret Revisionspartnerselskab
Copenhagen, Denmark
February 8, 2018